TB-500 Tracker App
Log Loading and Maintenance Phases, Monitor Pain Scores, and Track Recovery
TB-500 is a synthetic fragment of Thymosin Beta-4 (Ac-SDKP / N-terminal fragment), a naturally occurring actin-binding protein involved in tissue repair and inflammation regulation. Widely used in sports medicine research, TB-500 is studied for muscle and tendon repair, injury recovery acceleration, anti-inflammatory effects, and cardiovascular tissue healing. Shotlee tracks your loading phase, maintenance phase, pain scores, and stacking protocols in one free app.
15,000+
Peptide Users
4.8★
App Rating
Free
Always Free
What Is TB-500?
TB-500 is a synthetic peptide corresponding to the N-terminal fragment (Ac-SDKP) of Thymosin Beta-4 (Tb4), a ubiquitous 43-amino-acid protein found in high concentrations in platelets, wound fluid, and blood. Thymosin Beta-4 plays a central role in actin sequestration, cell migration, and tissue repair. TB-500 isolates and amplifies the most therapeutically active fragment of this protein.
In preclinical studies, TB-500 has shown consistent benefits for muscle fibre regeneration, tendon repair, cardiac tissue healing after ischaemia, and suppression of acute inflammatory cascades. It is frequently stacked with BPC-157 due to complementary mechanisms: BPC-157 acts primarily on GH receptor upregulation and angiogenesis, while TB-500 drives actin polymerisation and cell migration for structural repair.
Research Peptide — Not Approved for Human Use
TB-500 is not approved for human use by the FDA or in most jurisdictions. All available evidence is from preclinical and animal studies. Consult a licensed physician before considering any peptide protocol.
Protocol Options
2–2.5 mg
Twice weekly — Loading Phase (4–6 weeks)
Standard loading protocol to saturate tissue repair pathways. Administered subcutaneously or IM. Total weekly dose: 4–5 mg during loading.
2–2.5 mg
Once weekly — Maintenance Phase
Reduced frequency after loading phase to sustain healing benefits. Continued weekly for 4–8 weeks depending on recovery progress.
Mechanism of Action
Binds to G-actin monomers and sequesters them, modulating actin polymerisation dynamics — critical for enabling cell migration into wound sites and scaffold formation during tissue repair.
Promotes satellite cell (muscle stem cell) activation and migration to sites of muscle fibre damage, accelerating myogenic repair and reducing fibrotic scar formation.
Stimulates angiogenesis through upregulation of vascular endothelial growth factor (VEGF), improving blood supply and oxygen delivery to ischaemic or injured tissue.
Downregulates pro-inflammatory cytokines (particularly TNF-a and IL-1b) at injury sites while preserving the acute inflammatory signals needed for tissue remodelling.
Research Highlights
Muscle Repair
Faster
Preclinical studies show accelerated satellite cell recruitment and reduced fibrotic scarring vs controls in muscle laceration models.
Cardiac Healing
Yes
TB-500 (Tb4) has shown cardioprotective effects in post-MI animal models, including reduced infarct size and improved ventricular function.
Anti-Fibrotic
Dual
Acts on both tendon and muscle tissue simultaneously — reducing scar formation while promoting organised collagen re-deposition.
What to Track in Shotlee
Capture your full TB-500 protocol — loading phases, pain scores, mobility, and stacking data.
Injection Log
Record every TB-500 injection: date, dose (mg), site, and phase (loading vs maintenance). Build a complete protocol history.
Dose & Timing
Track whether you are in loading or maintenance phase. Log injection intervals to confirm protocol adherence across weeks.
Pain Scores
Log daily pain intensity (0–10 VAS) at the target injury site. Declining scores over weeks confirm healing response.
Range of Motion
Measure and record joint ROM (degrees) at each checkpoint. Objective mobility data correlates with tissue repair progress.
Healing Markers
Note functional milestones: when you returned to partial loading, full activity, or sport. Timestamped recovery markers matter.
BPC-157 Stack
Log BPC-157 co-administration alongside TB-500. Track each compound separately to attribute improvements accurately.
Loading vs Maintenance: Why the Phase Structure Matters
The loading/maintenance structure of TB-500 protocols reflects how actin-binding peptides achieve therapeutic tissue concentrations. The loading phase (2–2.5 mg twice weekly for 4–6 weeks) establishes sufficient peptide presence in injured tissue to drive meaningful cell migration and angiogenesis. Skipping or shortening loading often produces weaker results.
The maintenance phase (2–2.5 mg once weekly) sustains the repair environment while the body completes structural remodelling. The total protocol is typically 8–12 weeks from loading start to maintenance end. Tracking your phase start and end dates in Shotlee lets you retrospectively correlate dose timing with pain score and mobility improvements.
Track Phase Transitions in Shotlee
Use Shotlee notes to mark when you transition from loading to maintenance. This creates a clean timeline for assessing dose-response across both phases.
Protocol FAQs
In preclinical research, TB-500 is studied for muscle and tendon repair, injury recovery acceleration, anti-inflammatory effects, cardiovascular tissue healing, and reduced fibrotic scarring. It is not approved for human use.
Standard protocols use a loading phase of 2–2.5 mg subcutaneously or IM twice weekly for 4–6 weeks, followed by a maintenance phase of 2–2.5 mg once weekly for 4–8 weeks. Total protocol is typically 8–12 weeks.
TB-500 and BPC-157 are frequently combined in research protocols. They act through complementary mechanisms — TB-500 via actin binding and cell migration, BPC-157 via GH receptor upregulation and angiogenesis. Log both compounds separately in Shotlee to track individual contributions.
Research protocol users typically report pain reduction within 2–3 weeks of starting the loading phase, with functional mobility improvements over 4–8 weeks. Track pain scores and range of motion in Shotlee from day one to capture your personal response curve.
TB-500 refers specifically to the N-terminal fragment (Ac-SDKP) of Thymosin Beta-4, not the full 43-amino-acid protein. It is believed to contain the primary bioactive region responsible for actin binding, cell migration, and tissue repair — but it is a truncated synthetic analogue, not identical to native Tb4.
References
- [1]ReviewGoldstein AL, Hannappel E, Kleinman HK. "Thymosin b4: actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med. 2005;11(9):421-9.
- [2]ReviewPhilp D, Kleinman HK. "Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide." Ann N Y Acad Sci. 2010;1194:81-6.
- [3]ReviewSosne G, Kleinman HK. "Key thymosin beta 4 mechanisms of action for eye, skin, and heart." Expert Opin Biol Ther. 2015;15(Suppl 1):S187-91.
Track Your TB-500 Protocol in Shotlee
Log loading and maintenance doses, monitor pain scores, and document your injury recovery timeline — all free in Shotlee.
🚀 Use Shotlee for Free